• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / Posters2 / 20123 / Nature: Serine is a natural ligand and allosteric activator of pyruvate...

Nature: Serine is a natural ligand and allosteric activator of pyruvate kinase M2

24 December 2012/in 2012, Discovery

Nature: Serine is a natural ligand and allosteric activator of pyruvate kinase M2

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2012-12-24 12:17:082024-02-12 16:05:21Nature: Serine is a natural ligand and allosteric activator of pyruvate kinase M2

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH Link to: Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110... Link to: Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients Link to: Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial in Advanced...
Scroll to top Scroll to top Scroll to top